Is ABDOMINAL PAIN a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed ABDOMINAL PAIN.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 237 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported ABDOMINAL PAIN to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and ABDOMINAL PAIN. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause ABDOMINAL PAIN, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes ABDOMINAL PAIN. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if ABDOMINAL PAIN ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing ABDOMINAL PAIN: 237
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where ABDOMINAL PAIN is a reported side effect: 7.1193%

FDA reports of any drug causing ABDOMINAL PAIN : 70909
Average percentage for all medicated patients where ABDOMINAL PAIN is reported as a complication: 0.4444%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with ABDOMINAL PAIN:

ASPIRIN (4864 patients)
HUMIRA (4791 patients)
HEPARIN SODIUM INJECTION (4734 patients)
MIRENA (4359 patients)
YAZ (3774 patients)
YASMIN (3595 patients)
VIOXX (3468 patients)
FOSAMAX (3311 patients)
NEXIUM (2997 patients)
SANDOSTATIN LAR (2915 patients)
PREDNISONE (2893 patients)
ACCUTANE (2641 patients)
LASIX (2384 patients)
OMEPRAZOLE (2269 patients)
LIPITOR (2266 patients)
REMICADE (2264 patients)
LISINOPRIL (2174 patients)
SEROQUEL (2156 patients)
SYNTHROID (2079 patients)
ZOMETA (2056 patients)
METHOTREXATE (1946 patients)
ACETAMINOPHEN (1872 patients)
PRILOSEC (1819 patients)
PROTONIX (1799 patients)
FOLIC ACID (1751 patients)
IBUPROFEN (1704 patients)
XANAX (1691 patients)
AMBIEN (1642 patients)
COUMADIN (1617 patients)
ZOFRAN (1578 patients)
PREVACID (1566 patients)
NEURONTIN (1558 patients)
ATENOLOL (1536 patients)
ALBUTEROL (1516 patients)
FUROSEMIDE (1448 patients)
ZOLOFT (1441 patients)
METFORMIN HCL (1439 patients)
HYDROCHLOROTHIAZIDE (1432 patients)
OXYCONTIN (1424 patients)
SIMVASTATIN (1385 patients)
BYETTA (1381 patients)
ATIVAN (1350 patients)
ENBREL (1319 patients)
VICODIN (1307 patients)
LEVOTHYROXINE SODIUM (1257 patients)
NORVASC (1244 patients)
PLAVIX (1240 patients)
PERCOCET (1230 patients)
LEXAPRO (1227 patients)
PAXIL (1223 patients)
DEXAMETHASONE (1221 patients)
POTASSIUM CHLORIDE (1206 patients)
LORAZEPAM (1205 patients)
EXJADE (1200 patients)
CYMBALTA (1153 patients)
PREDNISOLONE (1141 patients)
AREDIA (1136 patients)
CELEBREX (1134 patients)
CIMZIA (1117 patients)
LYRICA (1116 patients)
TOPROL-XL (1101 patients)
DIGOXIN (1092 patients)
PREDNISONE TAB (1092 patients)
ZOCOR (1091 patients)
LEVAQUIN (1074 patients)
SOLIRIS (1066 patients)
MORPHINE (1062 patients)
FLUOROURACIL (1058 patients)
NEXAVAR (1053 patients)
CRESTOR (1044 patients)
GABAPENTIN (1034 patients)
ALLOPURINOL (1006 patients)
FORTEO (1005 patients)
OXYCODONE HCL (987 patients)
LANTUS (949 patients)
WARFARIN SODIUM (949 patients)
CARBOPLATIN (946 patients)
VITAMIN D (940 patients)
SINGULAIR (930 patients)
EFFEXOR (930 patients)
DROSPIRENONE AND ETHINYL ESTRADIOL (923 patients)
LORTAB (894 patients)
GLEEVEC (885 patients)
PROZAC (884 patients)
MULTI-VITAMINS (879 patients)
ZANTAC (866 patients)
AMOXICILLIN (862 patients)
DIOVAN (857 patients)
COMPAZINE (842 patients)
CALCIUM (841 patients)
CLONAZEPAM (838 patients)
AMLODIPINE (835 patients)
PREMARIN (829 patients)
INSULIN (826 patients)
DURAGESIC-100 (825 patients)
ALPRAZOLAM (824 patients)
REGLAN (823 patients)
METOPROLOL TARTRATE (806 patients)
LOVENOX (801 patients)
DECADRON (797 patients)
DILAUDID (795 patients)
CIPROFLOXACIN (792 patients)
AVASTIN (787 patients)
ZELNORM (784 patients)
TRAMADOL HCL (779 patients)
MULTI-VITAMIN (774 patients)
FENTANYL (772 patients)
CISPLATIN (772 patients)
CYCLOPHOSPHAMIDE (768 patients)
ADVAIR DISKUS 100/50 (760 patients)
ZYRTEC (744 patients)
CELEXA (731 patients)
WELLBUTRIN (726 patients)
COLACE (707 patients)
COREG (705 patients)
RANITIDINE (699 patients)
HEPARIN SODIUM (697 patients)
LANSOPRAZOLE (695 patients)
DIANEAL (678 patients)
FLAGYL (669 patients)
GLUCOPHAGE (655 patients)
SPIRONOLACTONE (654 patients)
FLUCONAZOLE (644 patients)
PROMETHAZINE (641 patients)
ZETIA (640 patients)
OXALIPLATIN (638 patients)
KLONOPIN (628 patients)
TYLENOL (628 patients)
ASCORBIC ACID (628 patients)
TYLENOL (CAPLET) (628 patients)
ACTOS (625 patients)
ALLEGRA (625 patients)
TAXOTERE (624 patients)
ZITHROMAX (622 patients)
XELODA (622 patients)
BENADRYL (621 patients)
PHENERGAN (619 patients)
ONDANSETRON (613 patients)
CHANTIX (613 patients)
METOCLOPRAMIDE (613 patients)
MORPHINE SULFATE (609 patients)
CYCLOSPORINE (600 patients)
PEPCID (597 patients)
NAPROXEN (589 patients)
NITROGLYCERIN (589 patients)
TRAZODONE HCL (588 patients)
BEVACIZUMAB (587 patients)
CAPECITABINE (584 patients)
PANTOPRAZOLE (583 patients)
CLONIDINE (583 patients)
AMITRIPTYLINE HCL (581 patients)
REVLIMID (580 patients)
VITAMIN B-12 (575 patients)
PLAN B ONE-STEP (573 patients)
FLEXERIL (572 patients)
IRON (565 patients)
METRONIDAZOLE (555 patients)
CALCIUM CARBONATE (548 patients)
AUGMENTIN '125' (537 patients)
MIRALAX (532 patients)
ULTRAM (531 patients)
BONIVA (531 patients)
LACTULOSE (530 patients)
VELCADE (528 patients)
METOPROLOL (525 patients)
ACYCLOVIR (523 patients)
ARANESP (522 patients)
NEORAL (521 patients)
ZYPREXA (519 patients)
VITAMIN E (519 patients)
AVELOX (519 patients)
CIPRO (516 patients)
ENALAPRIL MALEATE (514 patients)
FLONASE (513 patients)
DIAZEPAM (512 patients)
MOTRIN (509 patients)
METFORMIN (507 patients)
COZAAR (505 patients)
HYDROCODONE (504 patients)
TAXOL (502 patients)
VALIUM (501 patients)
CLARITIN (500 patients)
BACTRIM (499 patients)
ACTONEL (498 patients)
RISPERDAL (492 patients)
RAMIPRIL (492 patients)
VANCOMYCIN (491 patients)
FISH OIL (491 patients)
ALLI (485 patients)
FERROUS SULFATE TAB (481 patients)
TOPAMAX (470 patients)
CEPHALEXIN (469 patients)
MYCOPHENOLATE MOFETIL (465 patients)
AVONEX (463 patients)
LOPRESSOR (461 patients)
SPIRIVA (460 patients)
ACIPHEX (457 patients)
DIFLUCAN (453 patients)
EPOGEN (453 patients)
CITALOPRAM HYDROBROMIDE (453 patients)
TYSABRI (453 patients)
SUTENT (451 patients)
METHYLPREDNISOLONE (450 patients)
ALTACE (450 patients)
FAMOTIDINE (448 patients)
SOLU-MEDROL (446 patients)
GLIPIZIDE (446 patients)
ORTHO EVRA (445 patients)
DOXYCYCLINE (445 patients)
PACLITAXEL (444 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about ABDOMINAL PAIN and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.